Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol

Paul Zarogoulidis; Ioannis Kioumis; Sofia Lampaki; John Organtzis; Konstantinos Porpodis; Dionysios Spyratos; Georgia Pitsiou; Dimitris Petridis; Athanasia Pataka; Haidong Huang; Qiang Li; Lonny Yarmus; Wolfgang Hohenforst-Schmidt; Nikolaos Pezirkianidis; Konstantinos Zarogoulidis

doi:10.2147/DDDT.S66576

Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol

Paul Zarogoulidis, Ioannis Kioumis, Sofia Lampaki, John Organtzis, Konstantinos Porpodis, Dionysios Spyratos, Georgia Pitsiou, Dimitris Petridis, Athanasia Pataka, Haidong Huang, Qiang Li, Lonny Yarmus, Wolfgang Hohenforst-Schmidt, Nikolaos Pezirkianidis, Konstantinos Zarogoulidis

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Background: At this time, several antibiotics have been investigated as possibilities for aerosol administration, but local therapy has been found to be more efficient in several diseases. Materials and methods: The drugs linezolid (Zyvox), vancomycin (Voncon), and daptomycin (Cubicin) were tested with three jet nebulizers with seven different residual cups and different loadings. Moreover, three ultrasound nebulizers were again tested with these drugs, with different loadings and mouthpiece attachments. Results: When drugs are combined with particular cup designs, they significantly lower the droplet size to 1.60 and 1.80 μm, which represents the best combination of Zyvox and cup G and Cubicin and cup D, respectively. Cup design D is suggested as the most effective cup for lowering the droplet size (2.30 μm) when considering a higher loading level (8 mL). Conclusion: Modification of current drugs from dry powder to solution is possible, and the residual cup design plays the most important role in droplet size production when the nebulization systems have the same properties.

Original language	English (US)
Pages (from-to)	1065-1072
Number of pages	8
Journal	Drug Design, Development and Therapy
Volume	8
DOIs	https://doi.org/10.2147/DDDT.S66576
State	Published - Aug 12 2014

Keywords

Aerosol
Daptomycin
Jet nebulizers
Linezolid
Ultrasound nebulizers
Vancomycin

ASJC Scopus subject areas

Pharmacology
Pharmaceutical Science
Drug Discovery

Access to Document

10.2147/DDDT.S66576

Fingerprint Dive into the research topics of 'Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol'. Together they form a unique fingerprint.

Cite this

Zarogoulidis, P., Kioumis, I., Lampaki, S., Organtzis, J., Porpodis, K., Spyratos, D., Pitsiou, G., Petridis, D., Pataka, A., Huang, H., Li, Q., Yarmus, L., Hohenforst-Schmidt, W., Pezirkianidis, N., & Zarogoulidis, K. (2014). Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol. Drug Design, Development and Therapy, 8, 1065-1072. https://doi.org/10.2147/DDDT.S66576

Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol. / Zarogoulidis, Paul; Kioumis, Ioannis; Lampaki, Sofia; Organtzis, John; Porpodis, Konstantinos; Spyratos, Dionysios; Pitsiou, Georgia; Petridis, Dimitris; Pataka, Athanasia; Huang, Haidong; Li, Qiang; Yarmus, Lonny; Hohenforst-Schmidt, Wolfgang; Pezirkianidis, Nikolaos; Zarogoulidis, Konstantinos.

In: Drug Design, Development and Therapy, Vol. 8, 12.08.2014, p. 1065-1072.

Research output: Contribution to journal › Article › peer-review

Zarogoulidis, P, Kioumis, I, Lampaki, S, Organtzis, J, Porpodis, K, Spyratos, D, Pitsiou, G, Petridis, D, Pataka, A, Huang, H, Li, Q, Yarmus, L, Hohenforst-Schmidt, W, Pezirkianidis, N & Zarogoulidis, K 2014, 'Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol', Drug Design, Development and Therapy, vol. 8, pp. 1065-1072. https://doi.org/10.2147/DDDT.S66576

Zarogoulidis, Paul ; Kioumis, Ioannis ; Lampaki, Sofia ; Organtzis, John ; Porpodis, Konstantinos ; Spyratos, Dionysios ; Pitsiou, Georgia ; Petridis, Dimitris ; Pataka, Athanasia ; Huang, Haidong ; Li, Qiang ; Yarmus, Lonny ; Hohenforst-Schmidt, Wolfgang ; Pezirkianidis, Nikolaos ; Zarogoulidis, Konstantinos. / Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol. In: Drug Design, Development and Therapy. 2014 ; Vol. 8. pp. 1065-1072.

@article{8bd12bf1e4fa424b84e4fcbeff9349d3,

title = "Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol",

abstract = "Background: At this time, several antibiotics have been investigated as possibilities for aerosol administration, but local therapy has been found to be more efficient in several diseases. Materials and methods: The drugs linezolid (Zyvox), vancomycin (Voncon), and daptomycin (Cubicin) were tested with three jet nebulizers with seven different residual cups and different loadings. Moreover, three ultrasound nebulizers were again tested with these drugs, with different loadings and mouthpiece attachments. Results: When drugs are combined with particular cup designs, they significantly lower the droplet size to 1.60 and 1.80 μm, which represents the best combination of Zyvox and cup G and Cubicin and cup D, respectively. Cup design D is suggested as the most effective cup for lowering the droplet size (2.30 μm) when considering a higher loading level (8 mL). Conclusion: Modification of current drugs from dry powder to solution is possible, and the residual cup design plays the most important role in droplet size production when the nebulization systems have the same properties.",

keywords = "Aerosol, Daptomycin, Jet nebulizers, Linezolid, Ultrasound nebulizers, Vancomycin",

author = "Paul Zarogoulidis and Ioannis Kioumis and Sofia Lampaki and John Organtzis and Konstantinos Porpodis and Dionysios Spyratos and Georgia Pitsiou and Dimitris Petridis and Athanasia Pataka and Haidong Huang and Qiang Li and Lonny Yarmus and Wolfgang Hohenforst-Schmidt and Nikolaos Pezirkianidis and Konstantinos Zarogoulidis",

year = "2014",

month = aug,

day = "12",

doi = "10.2147/DDDT.S66576",

language = "English (US)",

volume = "8",

pages = "1065--1072",

journal = "Drug Design, Development and Therapy",

issn = "1177-8881",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol

AU - Zarogoulidis, Paul

AU - Kioumis, Ioannis

AU - Lampaki, Sofia

AU - Organtzis, John

AU - Porpodis, Konstantinos

AU - Spyratos, Dionysios

AU - Pitsiou, Georgia

AU - Petridis, Dimitris

AU - Pataka, Athanasia

AU - Huang, Haidong

AU - Li, Qiang

AU - Yarmus, Lonny

AU - Hohenforst-Schmidt, Wolfgang

AU - Pezirkianidis, Nikolaos

AU - Zarogoulidis, Konstantinos

PY - 2014/8/12

Y1 - 2014/8/12

N2 - Background: At this time, several antibiotics have been investigated as possibilities for aerosol administration, but local therapy has been found to be more efficient in several diseases. Materials and methods: The drugs linezolid (Zyvox), vancomycin (Voncon), and daptomycin (Cubicin) were tested with three jet nebulizers with seven different residual cups and different loadings. Moreover, three ultrasound nebulizers were again tested with these drugs, with different loadings and mouthpiece attachments. Results: When drugs are combined with particular cup designs, they significantly lower the droplet size to 1.60 and 1.80 μm, which represents the best combination of Zyvox and cup G and Cubicin and cup D, respectively. Cup design D is suggested as the most effective cup for lowering the droplet size (2.30 μm) when considering a higher loading level (8 mL). Conclusion: Modification of current drugs from dry powder to solution is possible, and the residual cup design plays the most important role in droplet size production when the nebulization systems have the same properties.

AB - Background: At this time, several antibiotics have been investigated as possibilities for aerosol administration, but local therapy has been found to be more efficient in several diseases. Materials and methods: The drugs linezolid (Zyvox), vancomycin (Voncon), and daptomycin (Cubicin) were tested with three jet nebulizers with seven different residual cups and different loadings. Moreover, three ultrasound nebulizers were again tested with these drugs, with different loadings and mouthpiece attachments. Results: When drugs are combined with particular cup designs, they significantly lower the droplet size to 1.60 and 1.80 μm, which represents the best combination of Zyvox and cup G and Cubicin and cup D, respectively. Cup design D is suggested as the most effective cup for lowering the droplet size (2.30 μm) when considering a higher loading level (8 mL). Conclusion: Modification of current drugs from dry powder to solution is possible, and the residual cup design plays the most important role in droplet size production when the nebulization systems have the same properties.

KW - Aerosol

KW - Daptomycin

KW - Jet nebulizers

KW - Linezolid

KW - Ultrasound nebulizers

KW - Vancomycin

UR - http://www.scopus.com/inward/record.url?scp=84906223626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906223626&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S66576

DO - 10.2147/DDDT.S66576

M3 - Article

C2 - 25143711

AN - SCOPUS:84906223626

VL - 8

SP - 1065

EP - 1072

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -